Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
Recruitment status was: Recruiting
RATIONALE: Erlotinib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or progressive glioblastoma multiforme.
Brain and Central Nervous System Tumors
Drug: erlotinib hydrochloride
|Study Design:||Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase II Study Trial Of Tarceva In Patients With Recurrent/Progressive Glioblastoma Multiforme|
- Response rate [ Designated as safety issue: No ]
- Progression-free survival [ Designated as safety issue: No ]
- Overall survival [ Designated as safety issue: No ]
- Efficacy of erlotinib in inhibiting epidermal growth factor receptor (EGFR) signaling [ Designated as safety issue: No ]
- Efficacy of tumor EGFR amplification in predicting response to treatment [ Designated as safety issue: No ]
|Study Start Date:||August 2002|
- Determine the response rate of patients with recurrent or progressive glioblastoma multiforme treated with erlotinib.
- Determine the progression-free and overall survival of patients treated with this drug.
OUTLINE: Patients receive oral erlotinib daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed for survival.
PROJECTED ACCRUAL: A total of 73 patients will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00054496
|United States, Ohio|
|Cleveland Clinic Taussig Cancer Center|
|Cleveland, Ohio, United States, 44195|
|Study Chair:||Michael A. Vogelbaum, MD, PhD||The Cleveland Clinic|